Through this partnership, GenScript will provide exclusive preferential rates along with technical guidance from experienced scientists across its extensive range of biotechnology services and products to NSG Bio residents.

This initiative empowers startups and biotech firms within the NSG Bio community, facilitating easier access to state-of-the-art technologies and services, thereby enhancing innovation and speeding up the transition from research to commercialization.

Since its founding in 2019, NSG Bio has supported innovators in developing transformative solutions across health, biomedical, agrifood, and industrial biotechnology sectors. The incubator specialises in precision medicine, nucleic acid technologies, AI-driven drug discovery, synthetic biology, and other groundbreaking areas. With Singapore's largest co-working biotech laboratory and office spaces and extensive networks of local and international partners, suppliers, and industry experts, NSG Bio has supported over 50 resident companies, fostering their growth and success.

Dr Janice Jin, President of GenScript Asia Pacific said "By extending preferential pricing and technical expertise to residents of NSG Bio, we aim to foster greater innovation among emerging biotechnology companies, allowing them to allocate more resources toward achieving scientific breakthroughs and market readiness."

"NSG Bio partnership with GenScript represents a significant step forward in enabling our resident companies to access cutting-edge scientific capabilities and industry expertise. By deepening collaboration between leading global service providers and local biotech innovators, we are helping to catalyze impactful scientific advancements and reinforce Singapore's position as a global hub for biomedical innovation," said Daphne Teo, Chairwoman of the Board & Founder of NSG Bio.